Search Results - "Rosak, C"

Diabetic cardiomyopathy and diastolic heart failure – Difficulties with relaxation by Teupe, C, Rosak, C

“…Abstract Diabetic patients carry a four- to five-fold increased risk of heart failure. Hyperglycaemia plays a central role in the pathogenesis of diabetic…”
Get full text

Insulin glargine maintains equivalent glycemic control and better lipometabolic control than NPH insulin in type 1 diabetes patients who missed a meal by Rosak, C, Jung, R, Hofmann, U

“…Our goal was to investigate blood glucose and lipometabolism control in type 1 diabetes patients who missed breakfast and the accompanying insulin injection of…”
Get more information

Rosiglitazone plus metformin is effective and well tolerated in clinical practice: results from large observational studies in people with type 2 diabetes by Rosak, C, Petzoldt, R, Wolf, R, Reblin, T, Dehmel, B, Seidel, D

“…This study investigated the efficacy during daily practice of rosiglitazone (RSG) added to metformin (MET) in poorly controlled type 2 diabetes mellitus. Two…”
Get more information

Rosiglitazone is effective and well-tolerated in a range of therapeutic regimens during daily practice in patients with type 2 diabetes by Rosak, C, Standl, E, Reblin, T, Stammer, H, Seidel, D K

“…Subjects (N = 22,808) with inadequately controlled type 2 diabetes mellitus (T2DM) were included in a large 6-month observational study in Germany…”
Get more information

Typ-2-Diabetes – Therapie mit insulinotropen Substanzen by Rosak, C.

Get full text

Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations by Rosak, Christoph, Mertes, Gabriele

“…The alpha-glucosidase inhibitor acarbose has been used for more than 20 years in the management of hyperglycemia. Owing to its unique mode of action in the…”
Get full text

The effect of the timing and the administration of acarbose on postprandial hyperglycaemia by Rosak, C, Nitzsche, G, König, P, Hofmann, U

“…To clarify the optimum timing for ingestion of acarbose, a 100 mg dose of this oral hypoglycaemic agent was administered 30 min before, at the beginning, and…”
Get more information

Genetic Analysis of Adult-Onset Autoimmune Diabetes by HOWSON, Joanna M. M, ROSINGER, Silke, SMYTH, Deborah J, BOEHM, Bernhard O, TODD, John A

“…In contrast with childhood-onset type 1 diabetes, the genetics of autoimmune diabetes in adults are not well understood. We have therefore investigated the…”
Get full text

The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents by Rosak, Christoph

“…Type 2 diabetes results from the abnormal resistance of peripheral tissues to insulin and from the progressive insulin secretory failure of the pancreatic…”
Get full text

A Randomized Clinical Trial Comparing Breakfast, Dinner, or Bedtime Administration of Insulin Glargine in Patients With Type 1 Diabetes by HAMANN, Andreas, MATTHAEI, Stephan, ROSAK, Christoph, SILVESTER, Louise

“…A Randomized Clinical Trial Comparing Breakfast, Dinner, or Bedtime Administration of Insulin Glargine in Patients With Type 1 Diabetes Andreas Hamann , MD 1 ,…”
Get full text

Glycosuria with SGLT-2 inhibitors--a new treatment approach for type 2 diabetes mellitus by Rosak, C, Forst, T

“…A new mechanism of action in the form of sodium-glucose co-transporter-(SGLT-)2 inhibitors will be available shortly for the treatment of type 2 diabetic…”
Get full text

Automatic eating detection algorithm in overweight subjects with type 2 diabetes implanted with the TANTALUS® System by Bohdjalian, A, Weiner, R, Rosak, C, Karnieli, E, Assalia, A, Prager, G, Ludvik, B

Get full text

When diet and oral antidiabetics are no longer enough. Optimal management of the diabetic patient with insulin by Rosak, C

“…In recent years, the approach to the insulin treatment of type 2 diabetics has undergone a change. Age and clinical status of the patient are decisive…”
Get more information

Comparative studies on intermediary metabolism and hormonal counterregulation following human insulin (recombinant DNA) and purified pork insulin in man by Rosak, C, Althoff, P H, Enzmann, F, Schöffling, K

“…Human insulin (recombinant DNA) and purified pork insulin (PPI) were administered intravenously at a dosage of 0.075 U/kg in eight healthy men. Both insulins…”
Get full text

Aspartic acid at position 57 of the HLA-DQ beta chain is protective against future development of insulin-dependent (type 1) diabetes mellitus by Boehm, B O, Manfras, B, Rosak, C, Schöffling, K, Trucco, M

“…Insulin-dependent (Type I) diabetes mellitus is a chronic autoimmune disease. From studies in discordant twins and multiplex families a long prediabetic period…”
Get full text

Spontaneous platelet aggregation and coagulation parameters as risk factors for arterial occlusions in diabetics. Results of the PARD-study by Breddin, H K, Krzywanek, H J, Althoff, P, Kirchmaier, C M, Rosak, C, Schepping, M, Weichert, W, Ziemen, M, Schöffling, K, Uberla, K

“…PARD is a prospective study sponsored by the German Research Council with the aim to establish whether spontaneously enhanced platelet aggregation or changes…”
Get more information

TcR-alpha and TcR-beta dialellic RFLPs in insulin-dependent (type I) Caucasian diabetic patients by Boehm, B O, Manfras, B J, Rosak, C, Kuehnl, P, Schöffling, K, Trucco, M

“…We studied the association of a T-cell receptor (TcR) beta restriction fragment length polymorphism (RFLP) and a new TcR-alpha RFLP with insulin-dependent…”
Get more information

Evidence for increased endogenous dopaminergic inhibition of aldosterone secretion in prolactinoma by Jungmann, E, Schwedes, U, Althoff, P H, Rosak, C, Schöffling, K

“…Aldosterone responsiveness to consecutive i.v. injections of metoclopramide 1 mg, 2.5 mg and 10 mg was studied in 8 patients with prolactinoma and normally…”
Get more information

Late-onset form of congenital adrenal hyperplasia in the HLA-B14; DR1 haplotype is caused by a duplication in the 21-OH MHC gene region by Boehm, B O, Rosak, C, Kuehnl, P, Schöffling, K

Get more information

Endogenous dopaminergic inhibition of aldosterone and prolactin secretion is apparently not increased in primary aldosteronism by Jungmann, E, Althoff, P H, Rosak, C, Schwedes, U, Schöffling, K

“…To examine the previous suggestion that the endogenous dopaminergic activity would be increased in patients with primary aldosteronism, dose-response curves of…”
Get more information